PharmaGap Inc.
100 Sussex Drive
Ottawa
Ontario
K1A-0R6
Canada
Tel: 613-998-3400
Fax: 613-998-3399
Website: http://www.pharmagap.com/
Email: info@pharmagap.com
56 articles about PharmaGap Inc.
-
PharmaGap Inc. Announces Successful Completion of Liposomal Development With Significantly Improved Potency of Cancer Drug
9/12/2011
-
PharmaGap Inc. Completes Initial Close of Private Placement
7/13/2011
-
PharmaGap Inc. Lead Drug to Be Presented at American Association for Cancer Research 102nd Annual Meeting
2/11/2011
-
PharmaGap Inc. Provides Clinical Development Program Update
1/27/2011
-
PharmaGap Inc. Reports Early Results in Bladder Cancer; Announces Collaboration With Queen’s University to Pursue Development for Clinical Use
12/21/2010
-
PharmaGap Inc. Completes Private Placement of Equity Units
11/19/2010
-
PharmaGap Inc. Completes Conversion of NRC Debt to Shares
11/4/2010
-
PharmaGap Inc. Announces Successful Result From Toxicity Phase Of Latest Testing
10/21/2010
-
PharmaGap Inc. Announces Successful Result From Toxicity Phase Of Latest Testing
10/14/2010
-
PharmaGap Inc. Provides Guidance on Clinical Drug Development Program for Q4 2010
10/5/2010
-
PharmaGap Inc. Announces Completion of Private Placement
9/14/2010
-
PharmaGap Inc. Grants of Options to Directors and Officers; Approves Conversion of Debt to National Research Council of Canada
9/9/2010
-
PharmaGap Inc. Announces Closing of First Tranche of Private Placement
8/30/2010
-
PharmaGap Inc. Announces Offering of Equity Units of up to $3 million
8/11/2010
-
PharmaGap Inc. Reports Positive Safety Testing; Development of Key Diagnostic Tool
8/3/2010
-
PharmaGap Inc. Appoints Dr. Ken Sokoll to Lead Cancer Drug Program to Clinical Trials
7/29/2010
-
PharmaGap Inc. to Expand Board, Add Experienced Clinical Development Executive
6/28/2010
-
PharmaGap Inc. Sees 80% Reduction in Melanoma Cancer Cell Growth in Tests at Memorial Sloan-Kettering Cancer Center Proceeding to Animal Testing
6/24/2010
-
PharmaGap Inc. Seeks Licensing Deal
6/3/2010
-
PharmaGap Inc. Announces Appointment to Clinical Development Group; Search for Chief Operating Officer to Guide Lead Drug to Clinical Trials
6/1/2010